课题基金 / 基金详情

项目摘要

项目成果

David R Plas的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Cancer develops as a result of uncontrolled cell proliferation coupled with defects in the induction of programmed cell death. Two classes of genes that have been shown to prevent cell death are the pro-survival Bcl-2 family members, and the serine-threonine kinase Akt. Previous work with Akt has demonstrated that cells surviving in an Akt-dependent manner are characterized by increased cell size and a reliance on increased cell metabolism. The molecular mechanisms by which Akt controls cell size and metabolism are unclear. The tuberous sclerosis gene TSC2 is a potential substrate of Akt, and has been shown to regulate cell size when expressed together with its binding partner, TSC1. In this proposal, experiments will be performed to determine the molecular targets for Akt-dependent increases in cell size, metabolism, and survival. The effects of the expression of hamartin and tuberin on these same processes will be assessed, as well as the possibility that TSC2 is an Akt substrate. Specific aims: 1. Identify the major downstream targets of Akt in the control of cell size and survival. A. Determine the major phosphoproteins induced in hematopoietic cells by activation of Akt. B. Determine which of the major downstream targets of Akt transduce signals that maintain cellular viability, metabolism and size in the absence of growth factor. C. Characterize Akt-induced degradation of its substrates. 2. Test the role of the tuberous sclerosis genes in regulating cell size and survival in hematopoietic cells. A. Characterize changes in TSC1 and TSC2 expression in hematopoietic cells upon growth factor withdrawal. B. Express TSC1 and TSC2 in control, Bcl-xL- and activated Akt-expressing cells, and measure changes in cell cycle, size, viability and metabolism in the presence and absence of growth factor. C. Determine if TSC1 and TSC2 contribute to Akt effects on cell size or survival. Test the importance of the potential Akt phosphorylation sites in tuberin. Together, these studies will help define the roles of the proto-oncogene Akt and the tumor suppressor genes TSC1 and TSC2 in the deregulation of cell metabolism in cancers associated with these genes.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Co-targeting S6 and TAM kinases in PTEN-deficient glioblastoma
  • 批准号:
    10535467
  • 项目类别:
  • 资助金额:
    $41.28万
  • 财政年份:
    2019
  • 负责人:
    David R Plas
  • 依托单位:
Co-targeting S6 and TAM kinases in PTEN-deficient glioblastoma
  • 批准号:
    9887655
  • 项目类别:
  • 资助金额:
    $43.44万
  • 财政年份:
    2019
  • 负责人:
    David R Plas
  • 依托单位:
Co-targeting S6 and TAM kinases in PTEN-deficient glioblastoma
  • 批准号:
    10308048
  • 项目类别:
  • 资助金额:
    $41.28万
  • 财政年份:
    2019
  • 负责人:
    David R Plas
  • 依托单位:
Metabolic Adaptive Responses in Cancer
  • 批准号:
    8626366
  • 项目类别:
  • 资助金额:
    $41.21万
  • 财政年份:
    2013
  • 负责人:
    David R Plas
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: